Vimovo MAH Announcement

Grünenthal Pharma Limited are pleased to announce the completion of the transfer of the marketing authorisation for Vimovo (naproxen 500mg / esomeprazole 20mg) to Grünenthal Pharma Limited on March 1st 2021.

Grünenthal Pharma Limited are pleased to announce the completion of the transfer of the marketing authorisation for Vimovo (naproxen 500mg / esomeprazole 20mg) to Grünenthal Pharma Limited on March 1^st 2021.

The transfer is part of a US$ 922m deal between AstraZeneca and Grünenthal whereby Grünenthal acquired the Global rights to Vimovo (naproxen 500mg /esomeprazole 20mg) (ex US and Japan) and the European rights to Nexium (esomeprazole magnesium trihydrate).